Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All drugs

Niraparib

Stage Phase 1

Sponsor Massachusetts General Hospital

Modality small molecule

Class PARP inhibitor

Target PARP1/2

Sources

registry, as of 2026-11-07

https://clinicaltrials.gov/api/v2/studies?query.cond=glioma&query.term=IDH

ClinicalTrials.gov API v2: IDH-mutant glioma interventional records plus 34 individual records, retrieved 11.07.2026 (registry fields as entered by sponsors)

Brief source I16

registry, as of 2026-11-07

https://clinicaltrials.gov/study/NCT05406700

A Phase 0 Clinical Trial to Evaluate Drug Concentrations and Pharmacodynamic Parameters of Niraparib in Tumor Tissue of Patients With Surgically Accessible Recurrent IDH 1/2 Gliomas

ClinicalTrials.gov API v2 record, retrieved 2026-11-07

Studies

NCT05406700

Registry NCT05406700

Phase Phase 1

Status Active, not recruiting

Enrollment 16

Start 2023-05-18

Primary completion 2026-07

Study completion 2026-10

Catalyst Primary completion. 07.2026. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.